Abstracts tagged "systemic lupus erythematosus (SLE) and cytokines"

Abstract Number: 958 • 2019 ACR/ARP Annual Meeting
Identification of IFN-γ-producing Effector B Cells in Humans: Their Relevance to the Pathogenesis of Systemic Lupus Erythematosus
Kazuhiko Higashioka¹, Masahiro Ayano ², Yasutaka Kimoto ³, Hiroki Mitoma ², Mitsuteru Akahoshi ², Yojiro Arinobu ², Koichi Akashi ¹, Takahiko Horiuchi ⁴ and Hiroaki Niiro ⁵, ¹Department of Medicine and Biosystemic Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan, ²Department of Medicine and Biosystemic Science, Graduate School of Medical Sciences, Fukuoka, Japan, Fukuoka, Japan, ³Department of Internal Medicine, Kyushu University Beppu Hospital, Beppu, Japan, ⁴Department of Internal Medicine, Kyushu University Beppu Hospital, Beppu, Japan, Beppu, Japan, ⁵Clinical Education Centre, Kyushu University Hospital, Fukuoka, Japan, Fukuoka, Japan
Background/Purpose: Systemic lupus erythematosus (SLE) is an autoimmune, multi-systemic disease that potentially affects any organ in the body. Clinical efficacy of B cell-targeting therapy underscores…
Abstract Number: 2819 • 2019 ACR/ARP Annual Meeting
The Transcription Factor MAF Controls the Ability of T Peripheral Helper (Tph) Cells to Help B Cells
Alexandra Bocharnikov¹, Vanessa Wacleche ¹, Ye Cao ¹ and Deepak Rao ², ¹Brigham and Women's Hospital, Boston, ²Brigham and Women's Hospital, Boston, MA
Background/Purpose: Pathologic T cell-B cell interactions are hallmark features of many autoimmune diseases. PD-1hi CXCR5- T peripheral helper (Tph) cells are B cell-helper T cells…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].